News and Trends 25 Jul 2022
Drug that could be the first and only in Europe to treat rare brain condition recommended for marketing authorization
…acquired the global rights to NULIBRY and is responsible for the ongoing development and commercialization of NULIBRY in the United States and developing, manufacturing, and commercializing fosdenopterin globally. Sentynl and BridgeBio share…